Skip to main content
. 2015 Jun 1;35(6):488–497. doi: 10.1089/jir.2014.0209

FIG. 3.

FIG. 3.

The PPARα agonist WY-14643 enhances the antiviral effect of IFN-α against HCV in cells chronically exposed to low-dose IFN. (A) JFH1-infected Huh-7 cells were pretreated with 2 U/mL IFN-α±WY-14643 for 3 weeks, then treated with 20 U/mL IFN-α. STAT phosphorylation was examined up to 2 h posttreatment with 20 U/mL IFN-α; ISRE/GAS promoter activation, ISG expression, and HCV replication were monitored. (B) In cells pretreated with WY-14643 in addition to low-dose (2 U/mL) IFN-α, there was enhanced response to treatment with high-dose (20 U/mL) IFN-α, with significantly reduced JFH1 replication after 24 h, compared with cells pretreated with IFN alone. Graph demonstrates an average of 3 experimental replicates (*P<0.05). ISG, interferon stimulated gene.